All In Biotech

Drug Trial Radar · NCT07181161

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

283

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Jan 18, 2029

Study completion Jan 18, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Conditions

  • Metastatic Prostate Cancer

Interventions

  • AZD0516Drug

    AZD0516 will be administered via intravenous infusion.

  • AZD9574Drug

    AZD9574 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)Time frame: From Day 1 up to approximately 3 years
  2. Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs)Time frame: From Day 1 up to end of DLT period (approximately 21 days)
  3. Module 1: Parts B and C and Module 2: Part B: Percentage of participants with Prostate-Specific Antigen (PSA) 50 response rateTime frame: Up to approximately 2 years

Locations

52 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Fayetteville, Arkansas · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Towson, Maryland · Suspended

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Buffalo, New York · Suspended

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Myrtle Beach, South Carolina · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Barretos, Brazil · Not yet recruiting

  • Research Site

    Porto Alegre, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Wuhan, China · Not yet recruiting

  • Research Site

    Lyon, France · Withdrawn

  • Research Site

    Montpellier, France · Withdrawn

  • Research Site

    Saint-Herblain, France · Withdrawn

  • Research Site

    Suresnes, France · Withdrawn

  • Research Site

    Villejuif, France · Withdrawn

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Naples, Italy · Not yet recruiting

  • Research Site

    Roma, Italy · Not yet recruiting

  • Research Site

    Rozzano, Italy · Not yet recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Koszalin, Poland · Not yet recruiting

  • Research Site

    Piotrkow Trybunalski, Poland · Not yet recruiting

  • Research Site

    Przemyśl, Poland · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Barcelona, Spain · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.